Share on StockTwits

AstraZeneca plc (LON:AZN)‘s stock had its “hold” rating reaffirmed by equities researchers at Berenberg Bank in a research report issued on Thursday. They currently have a GBX 3,775 ($64.10) target price on the stock. Berenberg Bank’s price objective indicates a potential downside of 12.99% from the stock’s previous close.

AZN has been the subject of a number of other recent research reports. Analysts at Jefferies Group reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday. They now have a GBX 4,790 ($81.34) price target on the stock. Separately, analysts at Swedbank reiterated a “reduce” rating on shares of AstraZeneca plc in a research note on Friday, July 25th. They now have a GBX 3,670.49 ($62.33) price target on the stock. Finally, analysts at Panmure Gordon reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, July 24th. They now have a GBX 4,400 ($74.72) price target on the stock. Seven research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 4,062.63 ($68.99).

Shares of AstraZeneca plc (LON:AZN) traded down 0.14% on Thursday, hitting GBX 4338.50. The stock had a trading volume of 2,261,840 shares. AstraZeneca plc has a one year low of GBX 442.867 and a one year high of GBX 5750.00. The stock has a 50-day moving average of GBX 4379.56 and a 200-day moving average of GBX 4172.58. The company’s market cap is £54.752 billion.

AstraZeneca PLC (LON:AZN) is a global biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.